TY - JOUR
T1 - Selective determinants of inositol 1,4,5-trisphosphate and adenophostin A interactions with type 1 inositol 1,4,5-trisphosphate receptors
AU - Rossi, Ana M.
AU - Sureshan, Kana M.
AU - Riley, Andrew M.
AU - Potter, Barry V. L.
AU - Taylor, Colin W.
PY - 2010/11
Y1 - 2010/11
N2 - BACKGROUND AND PURPOSE Adenophostin A (AdA) is a potent agonist of inositol 1,4,5-trisphosphate receptors (IP3R). AdA shares with IP3 the essential features of all IP3R agonists, namely structures equivalent to the 4,5-bisphosphate and 6-hydroxyl of IP3, but the basis of its increased affinity is unclear. Hitherto, the 2'-phosphate of AdA has been thought to provide a supra-optimal mimic of the 1-phosphate of IP3.
EXPERIMENTAL APPROACH We examined the structural determinants of AdA binding to type 1 IP3R (IP(3)R1). Chemical synthesis and mutational analysis of IP(3)R1 were combined with 3H-IP3 binding to full-length IP(3)R1 and its N-terminal fragments, and Ca2+ release assays from recombinant IP(3)R1 expressed in DT40 cells.
KEY RESULTS Adenophostin A is at least 12-fold more potent than IP3 in functional assays, and the IP3-binding core (IBC, residues 224-604 of IP(3)R1) is sufficient for this high-affinity binding of AdA. Removal of the 2'-phosphate from AdA (to give 2'-dephospho-AdA) had significantly lesser effects on its affinity for the IBC than did removal of the 1-phosphate from IP3 (to give inositol 4,5-bisphosphate). Mutation of the only residue (R568) that interacts directly with the 1-phosphate of IP3 decreased similarly (by similar to 30-fold) the affinity for IP3 and AdA, but mutating R504, which has been proposed to form a cation-pi interaction with the adenine of AdA, more profoundly reduced the affinity of IP3R for AdA (353-fold) than for IP3 (13-fold).
CONCLUSIONS AND IMPLICATIONS The 2'-phosphate of AdA is not a major determinant of its high affinity. R504 in the receptor, most likely via a cation-pi interaction, contributes specifically to AdA binding.
AB - BACKGROUND AND PURPOSE Adenophostin A (AdA) is a potent agonist of inositol 1,4,5-trisphosphate receptors (IP3R). AdA shares with IP3 the essential features of all IP3R agonists, namely structures equivalent to the 4,5-bisphosphate and 6-hydroxyl of IP3, but the basis of its increased affinity is unclear. Hitherto, the 2'-phosphate of AdA has been thought to provide a supra-optimal mimic of the 1-phosphate of IP3.
EXPERIMENTAL APPROACH We examined the structural determinants of AdA binding to type 1 IP3R (IP(3)R1). Chemical synthesis and mutational analysis of IP(3)R1 were combined with 3H-IP3 binding to full-length IP(3)R1 and its N-terminal fragments, and Ca2+ release assays from recombinant IP(3)R1 expressed in DT40 cells.
KEY RESULTS Adenophostin A is at least 12-fold more potent than IP3 in functional assays, and the IP3-binding core (IBC, residues 224-604 of IP(3)R1) is sufficient for this high-affinity binding of AdA. Removal of the 2'-phosphate from AdA (to give 2'-dephospho-AdA) had significantly lesser effects on its affinity for the IBC than did removal of the 1-phosphate from IP3 (to give inositol 4,5-bisphosphate). Mutation of the only residue (R568) that interacts directly with the 1-phosphate of IP3 decreased similarly (by similar to 30-fold) the affinity for IP3 and AdA, but mutating R504, which has been proposed to form a cation-pi interaction with the adenine of AdA, more profoundly reduced the affinity of IP3R for AdA (353-fold) than for IP3 (13-fold).
CONCLUSIONS AND IMPLICATIONS The 2'-phosphate of AdA is not a major determinant of its high affinity. R504 in the receptor, most likely via a cation-pi interaction, contributes specifically to AdA binding.
KW - IP3 receptor
KW - structure-activity relationship
KW - adenophostin
KW - Ca2+signal
UR - http://www.scopus.com/inward/record.url?scp=77958558893&partnerID=8YFLogxK
UR - http://dx.doi.org/10.1111/j.1476-5381.2010.00947.x
U2 - 10.1111/j.1476-5381.2010.00947.x
DO - 10.1111/j.1476-5381.2010.00947.x
M3 - Article
SN - 0007-1188
VL - 161
SP - 1070
EP - 1085
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 5
ER -